← Back to Search

Wee1 Kinase Inhibitor

Adavosertib for Cancer

Phase 2
Waitlist Available
Led By Rahul R Aggarwal
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male patients willing to abstain or use barrier contraception (i.e. condoms) for the duration of the study and for 3 months after treatment stops
Cohort B: Patients with histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma (with clear cell component on pathology), who have been treated with at least one prior systemic therapy for locally advanced or metastatic disease, including either tyrosine kinase inhibitor and/or immune checkpoint inhibitor, with evidence of SETD2 mutation on CLIA-certified next generation sequencing panel
Must not have
Any known hypersensitivity or contraindication to the components of the study drug AZD1775
Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases - defined as metastasis having no evidence of progression or hemorrhage for at least 2 weeks after treatment; must be off any systemic corticosteroids for the treatment of brain metastases for at least 14 days prior to enrollment; patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Summary

This trial studies how well adavosertib works in patients with advanced or metastatic solid tumors that lack the SETD2 gene. Adavosertib may help stop tumor growth by blocking enzymes needed for cancer cells to grow. Adavosertib is a first-in-class, small-molecule reversible inhibitor of WEE1 kinase, previously shown to have clinical activity in various cancers.

Who is the study for?
This trial is for adults with advanced solid tumors that have spread and have a SETD2 mutation. They must have tried at least one therapy, be able to swallow pills, not be pregnant or breastfeeding, use contraception if fertile, and meet certain health criteria like specific blood cell counts.
What is being tested?
The trial is testing Adavosertib's effectiveness on patients with SETD2-deficient advanced solid tumors. It's a phase II study where the drug aims to block enzymes needed for tumor growth.
What are the potential side effects?
Potential side effects of Adavosertib may include fatigue, nausea, low blood cell counts leading to increased infection risk or bleeding problems, and other common chemotherapy-related reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a male willing to use condoms during the study and for 3 months after it ends.
Select...
I have advanced kidney cancer with a specific genetic change and have had previous treatment.
Select...
My bilirubin levels are within the normal range, even with liver issues or Gilbert's syndrome.
Select...
My cancer has spread, is not kidney cancer, and has a specific genetic change.
Select...
My kidney function, measured by creatinine levels or clearance, is within the required range.
Select...
I am mostly active and can care for myself.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not allergic to the study drug AZD1775.
Select...
I do not have active brain cancer or symptoms from previous brain metastases.
Select...
I do not have any severe illnesses or social situations that would prevent me from following the study's requirements.
Select...
I have been treated with a WEE1 inhibitor before.
Select...
I am not taking any medication or herbal supplements that affect CYP3A4 enzymes.
Select...
I have not had serious heart problems in the last 6 months.
Select...
I have experienced side effects worse than mild from previous treatments, excluding hair loss or loss of appetite.
Select...
I am not pregnant or breastfeeding.
Select...
I haven't taken any cancer drugs in the last 3 weeks or within their half-life period before starting AZD1775.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Objective response rate
Secondary study objectives
Clinical benefit rate
Duration of response
H3K36me3 mark
+2 more

Side effects data

From 2023 Phase 1 & 2 trial • 76 Patients • NCT02095132
80%
Lymphocyte count decreased
80%
Fatigue
80%
Hypoalbuminemia
80%
White blood cell decreased
80%
Vomiting
70%
Anemia
70%
Diarrhea
70%
Abdominal pain
70%
Nausea
60%
Anorexia
50%
Sinus tachycardia
50%
Cough
50%
Fever
50%
Pleural effusion
40%
Anxiety
40%
Neutrophil count decreased
40%
Aspartate aminotransferase increased
40%
Dyspnea
40%
Headache
40%
Platelet count decreased
30%
Alopecia
30%
Hypomagnesemia
30%
Insomnia
30%
Constipation
30%
Hypermagnesemia
30%
Pain
30%
Pain in extremity
30%
Dizziness
30%
Hypertension
30%
Dehydration
30%
Hypocalcemia
30%
Weight loss
20%
Allergic rhinitis
20%
Alanine aminotransferase increased
20%
Hematuria
20%
Hyponatremia
20%
Wound infection
20%
Atelectasis
20%
Gait disturbance
20%
Hyperkalemia
20%
Hypophosphatemia
20%
Hypokalemia
20%
Myalgia
20%
Nasal congestion
20%
Osteoporosis
20%
Productive cough
20%
Dry mouth
20%
Hypotension
20%
Peripheral sensory neuropathy
10%
Alkalosis
10%
Muscle weakness upper limb
10%
Lymphedema
10%
Eye disorders - Other, Visual disturbance
10%
Skin and subcutaneous tissue disorders - Other, SMEGMA
10%
Pulmonary edema
10%
Tumor pain
10%
Musculoskeletal and connective tissue disorder - Other, GROWTH PLATE ABNORMALITY
10%
Investigations - Other, ELEVATED LDH
10%
Infections and infestations - Other, Retropharyngeal infection
10%
Skin and subcutaneous tissue disorders - Other, HAIR DEPIGMENTATION
10%
Lethargy
10%
Bruising
10%
Localized edema
10%
Photophobia
10%
Sinus bradycardia
10%
Generalized muscle weakness
10%
Muscle weakness lower limb
10%
Urine output decreased
10%
Chest wall pain
10%
Malaise
10%
Skin ulceration
10%
Hypothyroidism
10%
Acute kidney injury
10%
Hyperglycemia
10%
Hypoxia
10%
Non-cardiac chest pain
10%
Back pain
10%
Blood bilirubin increased
10%
Blurred vision
10%
Chills
10%
Dyspepsia
10%
Dysphagia
10%
Fecal incontinence
10%
Gastritis
10%
Hyperhidrosis
10%
Hypernatremia
10%
Hypertriglyceridemia
10%
Infections and infestations - Other, C. DIFF INFECTION
10%
Infections and infestations - Other, E COLI
10%
Infections and infestations - Other, E. COLI
10%
Investigations - Other, BUN increased
10%
Investigations - Other, elevated LDH
10%
Lipase increased
10%
Metabolism and nutrition disorders - Other, CACHEXIA
10%
Mucositis oral
10%
Oculomotor nerve disorder
10%
Paresthesia
10%
Proteinuria
10%
Respiratory, thoracic and mediastinal disorders - Other,
10%
Respiratory, thoracic and mediastinal disorders - Other, TACHYPNEA
10%
Scoliosis
10%
Skin hypopigmentation
10%
Surgical and medical procedures - Other, G-tube placement
10%
Tinnitus
10%
Urinary retention
10%
Skin and subcutaneous tissue disorders - Other, TUMOR BLEEDING
10%
Urinary tract obstruction
10%
Alkaline phosphatase increased
10%
Bone pain
10%
Creatinine increased
10%
Dysgeusia
10%
Electrocardiogram QT corrected interval prolonged
10%
Investigations - Other, VIT D DEFICIENCY
10%
Hearing impaired
10%
Investigations - Other, bicarbonate serum low
10%
Neck pain
10%
Sore throat
100%
80%
60%
40%
20%
0%
Study treatment Arm
Part D, Rhabdomyosarcoma
Part A, Dose Level 1
Part A, Dose Level 2
Part A, Dose Level 3
Part A, Dose Level 4
Part A, Dose Level 5
Part A, PK Expansion
Part B, Neuroblastoma
Part C, Medulloblastoma/CNS PNET

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (adavosertib)Experimental Treatment1 Intervention
Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Adavosertib
2015
Completed Phase 2
~570

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Renal Cell Carcinoma (RCC) include targeted therapies, immunotherapies, and enzyme inhibitors. Targeted therapies, such as VEGFR inhibitors, work by blocking the blood supply to the tumor, effectively starving it of nutrients needed for growth. Immunotherapies, like checkpoint inhibitors, enhance the body's immune response against cancer cells. Enzyme inhibitors, such as adavosertib, target specific enzymes necessary for cancer cell proliferation, thereby halting tumor growth. These mechanisms are crucial for RCC patients as they offer personalized treatment options that can be more effective and have fewer side effects compared to traditional chemotherapy.
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,868 Previous Clinical Trials
41,010,777 Total Patients Enrolled
Rahul R AggarwalPrincipal InvestigatorYale University Cancer Center LAO

Media Library

Adavosertib (Wee1 Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03284385 — Phase 2
Renal Cell Carcinoma Research Study Groups: Treatment (adavosertib)
Renal Cell Carcinoma Clinical Trial 2023: Adavosertib Highlights & Side Effects. Trial Name: NCT03284385 — Phase 2
Adavosertib (Wee1 Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03284385 — Phase 2
~8 spots leftby Aug 2025